Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 in Overweight/Obesity and OSA (AMAZE 4)
NCT07571109Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- Jun 2028
- Countries
- 10
01
Overview
A Phase 3 trial of amycretin in obesity, obstructive sleep apnea (OSA), sponsored by Novo Nordisk. Started May 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesityobstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT07571109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571109.